• The Incyte Nordic Grant for Hematological Research

    Deadline for application:

    1st of October, 2024


The Incyte Nordic Grant for Hematological Research is intended to stimulate the interest for research in the field of hematological malignancies and to encourage young clinicians/researchers to participate in scientific advancement by supporting the realization of high quality research and development projects.


One or more unrestricted grants of up to 40,000 USD will be awarded annually, funded by Incyte Biosciences Nordic AB. The grant is awarded once per year. Each year an assessment will be conducted and a decision to continue the funding of the grant will be made by Incyte in consultation with the Grant Review Committee.

Applicants and application

Preclinical and clinical projects within malignant hematology are eligible, with a priority on projects focusing on leukemia/lymphoma.

Eligible applicants for the Grant are researchers active at a Nordic unit and performing research primarily taking place in the Nordic region. Priority will be given to applicants scheduled to present their dissertation within the next 18 months or has done so no more than three years ago.

Applications should contain a rationale and background of the project, the objectives, a description of methodology, defined timelines and a specified budget (with detailed budget cost breakdown).

Applications will be subject to the terms and conditions contained in the Attachment to this Charter.

Grant Review Committee

The Grant Review Committee consists of:

  • Professor Magnus Björkholm, chairman (Karolinska Institute – Sweden),
  • Professor Kari Remes (Turku University – Finland),
  • Harald Holte, MD, PhD (Oslo University – Norway)
  • The Medical Director of Incyte Biosciences Nordic AB, (without voting rights)

The Grant Review Committee will select the Project which will receive the grant funding. Decisions will be made based on majority voting. In case of a tie, the Committee chairman will cast the decisive vote.

Announcement of the winner(s) will be made before the end of the year and potentially advertised through trade media.


The intent is to award full or partial funding for one or more projects. However the total maximum funding amount shall not exceed 40.000 USD. The Committee also reserves the right to hand out parts or none of the Grant.

The recipient (or recipients) of the Grant commits to report to the Committee upon completion of the project. Within one year from the receipt of the funds, an interim report is to be submitted to the Committee.

Transparency Disclosure

A transparency disclosure – “This Project was supported by an unrestricted educational grant by Incyte Biosciences” – will be included in Project communications and publications.

Application Submission

Applications, maximum four (4) pages plus one (1) CV page, all together five (5) pages, should be sent as an electronic version to:

And one (1) paper copy addressed to:
The Incyte Nordic Grant for Hematological Research
c/o Incyte Biosciences Nordic AB
Barnhusgatan 3
111 23 Stockholm


Applications must be submitted by the 1st of October, 2024 to be considered for the Grant.


The recipient of the Grant will be notified in writing. Incyte may publish communications (e.g. trade media) about the grant (including the application process and the final outcome. Details on membership of the Grant Committee may be disclosed in such communications.

Click here for Grant Application Terms & Conditions.

On behalf of the Incyte Grant in Hematological Research Review Committee

Professor Magnus Björkholm, Chairman
Karolinska Institute, Sweden
Harald Holte, MD, PhD
Oslo University, Norway
Professor Kari Remes
Turku University, Finland
Julie Bekaert
Incyte Biosciences, Medical Director, Nordic